PTC Therapeutics Enters Material Definitive Agreement
Ticker: PTCT · Form: 8-K · Filed: Dec 29, 2025 · CIK: 1070081
Sentiment: neutral
Topics: material-definitive-agreement, corporate-action
Related Tickers: PTCT
TL;DR
PTC THERAPEUTICS (PTCT) signed a big deal on 12/29/25, details TBD.
AI Summary
On December 29, 2025, PTC Therapeutics, Inc. entered into a material definitive agreement. The filing does not disclose specific details of the agreement, such as the counterparty or financial terms.
Why It Matters
This filing indicates a significant new development for PTC Therapeutics, potentially involving partnerships, acquisitions, or licensing deals that could impact its future growth and product pipeline.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and implications of the agreement, which could be positive or negative for the company.
Key Players & Entities
- PTC Therapeutics, Inc. (company) — Filer
- December 29, 2025 (date) — Date of Report
FAQ
What is the nature of the material definitive agreement entered into by PTC Therapeutics?
The filing states that PTC Therapeutics, Inc. entered into a material definitive agreement on December 29, 2025, but does not provide specific details about the agreement itself.
Who is the counterparty to this material definitive agreement?
The filing does not disclose the name of the other party involved in the material definitive agreement.
What are the key financial terms or obligations associated with this agreement?
The filing does not specify any financial terms, obligations, or dollar amounts related to the material definitive agreement.
When was this material definitive agreement officially entered into?
The agreement was entered into on December 29, 2025, which is also the date of the report.
Does this agreement represent an acquisition, partnership, or licensing deal?
The filing does not specify the type of agreement; it is only categorized as a 'Material Definitive Agreement'.
Filing Stats: 759 words · 3 min read · ~3 pages · Grade level 11.6 · Accepted 2025-12-29 16:05:21
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share PTCT Nasdaq Glo
- $240.0 million — interest in the Royalty in exchange for $240.0 million in upfront cash consideration, and thre
- $20.0 million — itional cash purchase price payments of $20.0 million each conditioned upon receipt by RPI of
- $347.0 million — tioned upon receipt by RPI of more than $347.0 million of Assigned Royalty Payments (as define
- $363.0 million — he Purchase Agreement) arising in 2027, $363.0 million of Assigned Royalty Payments in respect
- $379.0 million — dar Year Net Sales arising in 2028, and $379.0 million of Assigned Royalty Payments in respect
Filing Documents
- tmb-20251229x8k.htm (8-K) — 41KB
- 0001104659-25-124837.txt ( ) — 153KB
- tmb-20251229.xsd (EX-101.SCH) — 3KB
- tmb-20251229_def.xml (EX-101.DEF) — 3KB
- tmb-20251229_lab.xml (EX-101.LAB) — 16KB
- tmb-20251229_pre.xml (EX-101.PRE) — 9KB
- tmb-20251229x8k_htm.xml (XML) — 5KB
01. Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement. On December 29, 2025, PTC Therapeutics, Inc. (the "Company"), Royalty Pharma Investments 2019 ICAV ("RPI"), and, for the limited purposes set forth in the Purchase Agreement (as defined below), Royalty Pharma plc, entered into an Amendment No. 2 to Amended and Restated Royalty Purchase Agreement (the "Amendment"), which amends that certain Amended and Restated Royalty Purchase Agreement, dated as of October 18, 2023, as amended by Amendment No. 1 dated June 17, 2024 (the "Purchase Agreement"). Under the Purchase Agreement, the Company sold to RPI a certain portion of the Company's right to receive sales-based royalty payments on worldwide net sales of Roche's Evrysdi (risdiplam) product and any other product developed pursuant to the License and Collaboration Agreement, dated as of November 23, 2011, by and among the Company, F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc. (together with F. Hoffman-La Roche Ltd, "Roche"), and, for the limited purposes set forth therein, the Spinal Muscular Atrophy Foundation (such payments, the "Royalty"). Pursuant to the Amendment, on December 29, 2025, the Company sold to RPI its retained interest in the Royalty in exchange for $240.0 million in upfront cash consideration, and three potential additional cash purchase price payments of $20.0 million each conditioned upon receipt by RPI of more than $347.0 million of Assigned Royalty Payments (as defined in the Purchase Agreement) in respect of Calendar Year Net Sales (as defined in the Purchase Agreement) arising in 2027, $363.0 million of Assigned Royalty Payments in respect of Calendar Year Net Sales arising in 2028, and $379.0 million of Assigned Royalty Payments in respect of Calendar Year Net Sales arising in 2029, respectively. The retained interest sold by the Company to RPI pursuant to the Amendment is equal to 9.5111% of the Royalty before the 2020 Assigned Royalty Cap (as defined in the Purchase Agreement) has be